# ClearPoint Neuro Inc. (CLPT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $389M  
**Price:** $13.75 (+1.18%)

> ClearPoint Neuro Inc. is a global device, cell, and gene therapy-enabling company specializing in precise navigation and delivery systems to the brain and spine. It develops and commercializes platforms like the ClearPoint system for minimally invasive neurosurgical procedures under real-time MRI guidance, supporting deep brain stimulation electrode insertions, biopsies, laser catheter placements, and pharmaceutical infusions. The company offers established clinical products alongside pre-clinical development services for controlled drug and device delivery, including the SmartFlow cannula for gene therapy and the ClearPoint Prism Neuro Laser Therapy System. ClearPoint Neuro also provides the IRRAflow system for active intracranial fluid management following its acquisition of IRRAS. Engaged with over 90 neurosurgery centers and more than 60 biologics and drug delivery partners worldwide across North America, Europe, Asia, and South America, it supports healthcare professionals, researchers, and biopharma in translational research, clinical trials, and patient treatments for complex neurological disorders. Founded in 1998 and headquartered in Solana Beach, California, ClearPoint Neuro maintains a dedicated focus on the neuro space through its Global Training and Innovation Center.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $37M | $23M | -$24M | -$26M | — |
| 2024 | $31M | $19M | -$20M | -$19M | — |
| 2023 | $24M | $14M | -$22M | -$22M | — |
| 2022 | $21M | $14M | -$16M | -$16M | — |
| 2021 | $16M | $11M | -$13M | -$14M | — |
| 2020 | $13M | $9M | -$6M | -$7M | — |
| 2019 | $11M | $7M | -$5M | -$6M | — |
| 2018 | $7M | $5M | -$5M | -$6M | — |
| 2017 | $7M | $4M | -$6M | -$7M | — |
| 2016 | $6M | $3M | -$7M | -$8M | — |
| 2015 | $5M | $3M | -$9M | -$8M | — |
| 2014 | $4M | $2M | -$5M | -$5M | — |
| 2013 | $4M | $3M | -$7M | -$7M | — |
| 2012 | $5M | $5M | -$3M | -$6M | — |
| 2011 | $4M | $3M | -$6M | -$8M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $98M | $70M | $28M | $46M | $49M |
| 2024 | $39M | $14M | $25M | $20M | — |
| 2023 | $43M | $21M | $21M | $23M | $10M |
| 2022 | $55M | $19M | $37M | $28M | $10M |
| 2021 | $66M | $17M | $49M | $54M | $10M |
| 2020 | $30M | $27M | $2M | $20M | $21M |
| 2019 | $12M | $7M | $5M | $6M | $2M |
| 2018 | $8M | $6M | $2M | $3M | $3M |
| 2017 | $14M | $8M | $6M | $9M | $5M |
| 2016 | $7M | $8M | -$756,069 | $3M | $4M |
| 2015 | $10M | $12M | -$2M | $5M | $8M |
| 2014 | $13M | $13M | -$100,330 | $9M | $11M |
| 2013 | $8M | $15M | -$7M | $4M | — |
| 2012 | $6M | $13M | -$8M | $2M | — |
| 2011 | $3M | $25M | -$22M | $145,478 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$24M | $522,000 | -$24M |
| 2024 | -$9M | $275,000 | -$9M |
| 2023 | -$14M | $717,000 | -$14M |
| 2022 | -$16M | $253,000 | -$16M |
| 2021 | -$13M | $168,000 | -$13M |
| 2020 | -$8M | $41,000 | -$8M |
| 2019 | -$3M | $10,000 | -$3M |
| 2018 | -$5M | $63,490 | -$5M |
| 2017 | -$6M | $26,752 | -$6M |
| 2016 | -$6M | $101,002 | -$6M |
| 2014 | -$7M | $48,129 | -$7M |
| 2013 | -$8M | $74,469 | -$8M |
| 2012 | -$7M | $127,453 | -$8M |
| 2011 | -$6M | $26,101 | -$6M |
| 2010 | -$8M | $61,704 | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CLPT)